PCR Panels redefining the landscape of lung cancer testing globally

New Delhi: The lung cancer PCR panel market size is projected to be worth US$ 513.9 million in 2023. The market is likely to surpass US$ 1.1 billion by 2033 at a CAGR of 8.0% during the forecast period.

Growing lung cancer incidences is aiding the market growth. Lung cancer targeted medicines and precision medicine are greatly aided by PCR panels. These panels assist in identifying patients who may benefit from targeted medicines or immunotherapies by identifying particular genetic abnormalities, including as mutations in genes like EGFR, ALK, ROS1, and others. The need for molecular diagnostics like PCR panels has been fueled by the creation and accessibility of innovative targeted medicines.

Other Drivers Propelling the Demand for Lung Cancer PCR Panel Market include:

Due to the rising incidence and prevalence of lung cancer worldwide, the market for lung cancer PCR panels is expanding. PCR panels provide a quick and reliable tool for identifying genetic mutations and variations linked with lung cancer, allowing for early detection and Personalised treatment options.

As per Future Market Insights, in recent years, the area of molecular diagnostics, especially PCR technology, has seen considerable breakthroughs. These developments have resulted in the creation of extremely sensitive and specific PCR panels capable of detecting various genetic changes in lung cancer samples.

Lung cancer identification is critical for improving patient outcomes. PCR panel’s aid in early detection by detecting particular mutations and changes linked to lung cancer. The emphasis on early detection and screening programs fuels the demand for PCR panels as an essential tool in lung cancer diagnosis.

Challenges for Companies /Manufacturers in the Lung Cancer PCR Panel Market:

The cost of PCR panels can be rather costly, which makes widespread implementation difficult, particularly in resource-limited environments. Differences in healthcare systems and nations have varying reimbursement regulations and coverage for molecular diagnostic testing, including PCR panels. Obtaining favorable reimbursement and showing cost-effectiveness can be difficult tasks, limiting market penetration.

In some circumstances, obtaining adequate lung cancer samples, such as tissue biopsies or liquid biopsies, might be difficult. The accuracy and reliability of PCR panel findings might be impacted by limited sample availability or poor sample quality.

Compliance with regulatory standards, such as getting required permissions and certifications, may be time-consuming and expensive. It is critical to follow quality assurance and quality control procedures to ensure the reliability and repeatability of PCR panel findings.

Opportunities in the Lung Cancer PCR Panel Market Industry:

In lung cancer diagnoses, liquid biopsy testing, which involves the measurement of circulating tumor DNA (ctDNA) or other biomarkers in the blood, is gaining traction. Because they may detect particular mutations and variations in ctDNA, PCR panels can be useful in liquid biopsy testing.

As more targeted medicines gain regulatory approval, PCR panels may be used as companion diagnostics to guarantee optimal patient selection and medication optimization.

The use of Next-generation sequencing (NGS) provides a chance to combine the benefits of PCR panels, such as high sensitivity and specificity, with the complete profiling capabilities of NGS, hence improving overall diagnostic capabilities in the Lung Cancer PCR Panel market.

Latest Trends in the Lung Cancer PCR Panel Market:

In lung cancer diagnoses, there is an increasing tendency towards thorough genetic profiling. PCR panels that identify several mutations and changes in a single test are being developed, enabling for more complete genomic analysis of lung cancer samples.

Biomarker testing, including the use of PCR panels, is becoming more common in lung cancer clinical trials. This pattern illustrates the increasing significance of biomarker-guided medicines and Personalised medicine techniques.

The discovery of novel targetable mutations in lung cancer is a continuing trend. These new mutations are being included in PCR panels, which provides doctors with crucial information for therapeutic decision-making.

Country-Wise Insights

Lung Cancer PCR Panel Market to Surge in the United States Due to Rising Prevalence of Lung Cancer.

The lung cancer PCR panel market industry in the United States is expected to reach a market size of US$ 223.2 million by 2033, expanding at a CAGR of 3.7%. Due to the increasing incidence of lung cancer nationwide the market is on the rise. Lung cancer affects a large number of people in the United States. Because of the high frequency of lung cancer, there is a significant market for PCR panels as a diagnostic tool to help in early identification, therapy selection, and disease monitoring. Furthermore, the availability of sophisticated molecular diagnostic technologies, such as PCR panels, boosts the growth of the country’s lung cancer PCR panel market.

Rising Demand for Lung Cancer PCR Panel Market is Due to the Growing Increasing Awareness and Screening Programs.

The lung cancer PCR panel market industry in the United Kingdom is expected to reach a market share of US$ 29.2 million, expanding at a CAGR of 3.8% during the forecast period. The public’s knowledge of lung cancer and the need of early diagnosis has grown in the United Kingdom. Screening programs and early detection measures aid in the growth of the lung cancer PCR panel market in the United Kingdom.

The UK has a strong research infrastructure and collaborative efforts between academia, research institutions, and the industry. These collaborations foster the development of advanced diagnostic technologies, including PCR panels, for lung cancer, driving market growth.

Notable Growth Expected in China’s Lung Cancer PCR Panel Market as Increasing Government Initiatives And Investments.

The lung cancer PCR panel market industry in China is anticipated to reach a market size of US$ 36.5 million, moving at a CAGR of 6.4% during the forecast period. The lung cancer PCR panel market industry in China is expected to grow prominently due to the increasing government initiatives and investments. The Chinese government has prioritized healthcare development and has invested in innovative diagnostic technology. Policies that encourage research and cooperation between academia and business all contribute to the growth of the lung cancer PCR panel market in China. Furthermore, the rising prevalence of lung cancer is driving demand for PCR panels as a diagnostic tool in China.

Advanced Healthcare Infrastructure to Drive Market Growth in Japan

The lung cancer PCR panel market industry in Japan is estimated to reach a market size of US$ 48.7 million by 2033, thriving at a CAGR of 6.2%. The market in Japan is predicted to grow because of its advanced healthcare infrastructure. Japan has a sophisticated medical technology and a well-developed healthcare system. The availability of improved diagnostic facilities, as well as a strong emphasis on early diagnosis and personalized medication, all contribute to the expansion of the lung cancer PCR panel market.

Demand for Lung Cancer PCR Panel Market is Rising Due to Increasing Technological Advancements.

The lung cancer PCR panel market industry in South Korea is expected to reach a market size of US$ 6.5 million, expanding at a CAGR of 6.0% during the forecast period. South Korea is well-known for its technology breakthroughs and healthcare innovation. The country’s strong emphasis on research and development, along with a favorable regulatory framework, leads to the growth of the lung cancer PCR panel market by allowing the development and commercialization of improved diagnostic technologies.

These insights are based on a report Lung Cancer PCR Panel Market by Future Market Insights.